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Abstract
Background: Granulocyte colony stimulating factor (G-CSF) is a growth factor essential for generation of
neutrophilic granulocytes. Apart from this hematopoietic function, we have recently uncovered potent
neuroprotective and regenerative properties of G-CSF in the central nervous system (CNS). The G-CSF receptor
and G-CSF itself are expressed in a motoneurons, G-CSF protects motoneurons, and improves outcome in the
SOD1(G93A) transgenic mouse model for amyotrophic lateral sclerosis (ALS). In vitro, G-CSF acts anti-
apoptotically on motoneuronal cells. Due to the pleiotrophic effects of G-CSF and the complexity of the SOD1
transgenic ALS models it was however not possible to clearly distinguish between directly mediated anti-
apoptotic and indirectly protective effects on motoneurons. Here we studied whether G-CSF is able to protect
motoneurons from purely apoptotic cell death induced by a monocausal paradigm, neonatal sciatic nerve
axotomy.
Results: We performed sciatic nerve axotomy in neonatal mice overexpressing G-CSF in the CNS and found that
G-CSF transgenic mice displayed significantly higher numbers of surviving lumbar motoneurons 4 days following
axotomy than their littermate controls. Also, surviving motoneurons in G-CSF overexpressing animals were larger,
suggesting additional trophic effects of this growth factor.
Conclusions: In this model of pure apoptotic cell death the protective effects of G-CSF indicate direct actions of
G-CSF on motoneurons in vivo. This shows that G-CSF exerts potent anti-apoptotic activities towards motoneurons
in vivo and suggests that the protection offered by G-CSF in ALS mouse models is due to its direct
neuroprotective activity.
Background
Granulocyte-colony-stimulating factor is a cytokine
that stimulates the proliferation and the differentiation
of myeloid precursors [1] and has been in clinical use
for more than 10 years in indications related to coun-
teracting chemotherapy-induced neutropenia or for
bone-marrow transplantations [2]. We and others dis-
covered that G-CSF also acts as a growth factor in the
brain, and shows protective and regenerative proper-
ties in a number of CNS disease models [3-6]. The
mechanisms leading to these beneficial effects likely
include a combination of anti-apoptotic activity on
neurons [5], stimulation of neurogenesis [5], enhance-
ment of vessel formation [3], mobilization of bone
marrow derived cells [4] and systemic anti-inflamma-
tory effects [5]. Recently we described that G-CSF was
protective in a mouse model of amyotrophic lateral
sclerosis (ALS), the major adult-onset motoneuron
disease. G-CSF treatment increased survival and
volume of spinal a motoneurons and protected moto-
neuronal cell lines (NSC34) in vitro against apoptotic
stimuli [6]. Importantly, while adult motoneurons pro-
minently express the receptor for G-CSF [6,7] our stu-
dies did not unequivocally show that G-CSF exerted
protection in this ALS model through its neuroprotec-
tive activity.
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able to protect motoneurons in vivo in a model of
neonatal sciatic nerve axotomy. This experimental
paradigm has been largely described, is thought to rely
almost exclusively on the apoptotic machinery [8], and
provides a powerful tool to study the neuroprotective
activity of growth factors towards motoneurons in vivo
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The G-CSF receptor is expressed on neonatal
motoneurons, and induced by axotomy
We have previously shown that the receptor of G-CSF
(G-CSFR) is expressed on motoneurons in the adult
spinal cord. We first determined whether the G-CSF
receptor was expressed on motoneurons during early
postnatal development. At postnatal day 9 (P9) we
noted expression of the receptor on a motoneurons in
the spinal cord ventral horn, identified by the following
criteria: Choline-Acetyltransferase (CHAT) expression,
an identifiable nucleolus, and a size larger than 300 μm
2
in the horizontal dimension (Figure 1). Invariably, all
motoneurons defined by these criteria expressed the
receptor.
The expression of G-CSF receptor is induced by neu-
rons under neurodegenerative conditions such as after
cerebral ischemia or in ALS, presumably as an endogen-
ous protective response [6,7]. We therefore examined
expression of the G-CSF receptor by quantitative PCR
of whole spinal cords 4 days following neonatal axotomy
of the right sciatic nerve (i.e. on postnatal day 9).
Indeed, we found that G-CSFR expression in the whole
spinal cord increased by 55% (p < 0.005) (Figure 2A).
To clarify whether this induction likely originated
from the injured motoneurons, we quantified fluorescent
staining intensities of ipsi- and contralateral motoneur-
ons from the lumbar spinal cord region. We detected
significantly stronger protein expression on ipsi- versus
contralateral motoneurons, suggesting that axotomized
motoneurons upregulate the receptor in response to
injury (p < 0,05) (Figure 2B).
In conclusion, the G-CSF receptor is expressed at the
neonatal stage and its expression is increased in
response to axotomy.
CNS- targeted overexpression of G-CSF protects
motoneurons against cell death in neonatal pups
Neonatal motoneuron death following sciatic nerve
axotomy constitutes a widely used and well- established
model of apoptotic motoneuron death that has been
used to examine protective effects of trophic factors.
We chose to use transgenic mice that overexpress G-
CSF in the CNS as an endogenous “delivery system” to
study effects of increased concentration of G-CSF on
the lesioned motoneurons. We used transgenic mice
harbouring a bidirectional tta-responsive construct
with expression cassettes for murine G-CSF and EYFP
(pBEG). These mice were crossed with mice expressing
the Tet-transactivator under control of the CaMKII a;-
promoter, similar to the approach used in Pitzer et al.
except for the use of the Thy1-driver used therein [7].
In the following we compare three types of transgene
combinations in littermates derived from crosses of
mice heterozygous for the transgene CaMKII-tTA and
heterozygous for pBEG. The three groups are a.) mice
not harbouring any transgene ("wt”), b.) mice harbour-
ing only the BEG2 transgene (which do not express
G-CSF), and c.) mice harbouring both the BEG2 trans-
gene and the CaMKII-tTA driver, that do express
G-CSF.
merge
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Figure 1 The G-CSF receptor is expressed by motoneurons in
the spinal cord of wt neonatal mice. (A-C) Double fluorescence
immunostaining of G-CSF receptor and CHAT (choline
acetyltransferase) in the neonatal mouse spinal cord ventral horn.
CHAT is used as a marker for motoneurons. All defined a motoneurons
express G-CSFR (indicated by an arrow). All photomicrographs with
40× original magnification (OM), size bar 25 μm.
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transgenes is mainly in the forebrain, release of G-CSF
in the spinal cord is expected from long corticospinal
axonal connections. Indeed, the CaMKIIa;-promoter
directed G-CSF overexpression in the forebrain leads to
a strong elevation of G-CSF levels in the neonatal brain
and spinal cord (P9; 28.00 ± 11.60 vs 0.24 ± 0.23 pg/mg
tissue protein; p < 0.05) (Figure 3).
Offspring from crosses of BEG and CaMK-tta trans-
genic mice were subjected to complete unilateral sciatic
nerve axotomy at postnatal day 5 (P5). We analyzed
effects on motoneuron survival in the lumbar section of
the spinal cord (L4/5 levels) after 4 days at P9. Examples
of the histological appearance of CHAT positive cells in
the ventral horn of the lumbar spinal cord of neonatal
mice after sciatic nerve axotomy are given in figure 4.
Our axotomy model results in a loss of approximately
40 - 50% of motoneurons 4 days after the injury (Figure
4A and 4B; Figure 5A and 5B), a result consistent with
other studies [8,9]. Already apparent from the histologi-
cal sections was that clearly more motoneurons survive
in mice with the G CSF transgene activated by the
CaMK-tta driver (BEG -/T CaMK -/T) (compare figure
4B and 4F).
We then quantified numbers of motoneurons in the
lumbar spinal cord of P9 neonatal mice contra- and
ipsilateral to the side of axotomy. The a motoneurons
were defined as (i) being situated in the ventral horn of
the lumbar region; (ii) having a clearly identifiable
nucleolus and staining positive for CHAT and (iii) hav-
ing a minimum cross-sectional area of 300 μm
2.
There was no difference between the absolute num-
bers of motoneurons on the contralateral side between
the three genotypes used, although there was a non-sig-
nificant trend for slightly higher numbers in the double-
transgenic group (BEG -/T CaMK-/T (7.03 ± 0.39 moto-
neurons/section) vs. BEG -/T CaMK-/- (5.98 ± 0.38) and
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Figure 2 G-CSF receptor expression after sciatic nerve
axotomy. (A) G-CSF receptor is upregulated after sciatic nerve
axotomy in spinal cord of neonatal mice. Quantitative PCR for G-CSF
receptor of spinal cords of axotomized or not neonatal mice
(induction of 55%; n = 3, **p < 0.005). (B) G-CSF receptor staining
intensity is stronger on the motoneurons after axotomy. Fluorescent
intensity of G-CSF receptor staining on motoneurons was calculated
on the ipsi- and contralateral side with an image processing
program (*p < 0.05, n = 49).
Figure 3 G-CSF concentration in the CNS. Levels of G-CSF are
higher in the brain and in the spinal cord of mice overexpressing
G-CSF (BEG -/T CaMK -/T) compared to wild type littermate controls
(BEG -/- CaMK -/-). G-CSF proteins were quantified by ELISA with
protein lysates from brain or spinal cord (n = 3, *p < 0.05).
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Page 3 of 9wt (6.1 ± 0.28); p = 0.1 by ANOVA) (Figure 5A). On the
axotomized side, sciatic nerve axotomy dramatically
decreased the numbers of motoneurons in animals lack-
ing the CaMK-tta driver transgene, whereas double
transgenic animals showed significantly higher numbers
of surviving motoneurons (BEG -/T CaMK-/T: 5.43 ±
0.28 motoneurons/section; BEG -/T CaMK-/-: 3.79 ±
0.27 and wt: 3.15 ± 0.20; p < 0.0001 by ANOVA and
Fisher’s LSD post-hoc analysis) (Figure 5B). We also
directly compared the fraction of surviving motoneurons
relative to the unlesioned side (Figure 5C). This analysis
revealed that only 50 - 60% of the motoneurons
survived in the genotypes lacking the CaMK-tta driver
transgene, whereas close to 90% of the motoneurons
survived in the double transgenic mice (i.e. in animals
overexpressing G-CSF) (BEG -/T CaMK-/T (88.76 ±
4.32%) vs. BEG -/T CaMK-/- (62.14 ± 4.22%) and wt
(51.93 ± 3.02%); p < 0.0001 by ANOVA and Fisher’s
LSD post-hoc analysis).
G-CSF preserves motoneuron size after axotomy
Our previous results in ALS mice had shown that the
shrinking of motoneurons in the SOD1(G93A) trans-
genic mice was partially restored by G-CSF treatment.
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Figure 4 Examples of the histological evaluation of CHAT positive cells in the ventral horn of the lumbar spinal cord of neonatal mice
after sciatic nerve axotomy. Sections from the lumbar spinal cord were stained with CHAT antibodies. (A, B) Examples of motoneurons in the
ventral horn contralateral and ipsilateral to the lesion side in BEG -/- CaMK -/- mice (wild type littermates). (C, D) Examples of lumbar sections
contra- and ipsilateral to the lesion from a BEG -/T CaMK -/- littermate (non-G-CSF expressing). (E, F) Examples of lumbar sections contra- and
ipsilateral to the lesion from a G-CSF overexpressor (BEG -/T CaMK -/T mouse). (B, D, F) There are more CHAT-positive cells detectable 4 days
after axotomy on the ipsilateral side in mice overexpressing G-CSF (BEG -/T CaMK -/T). All photomicrographs with 20× original magnification
(OM), size bar 50 μM.
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Page 4 of 9To determine whether this was also the case after sciatic
nerve axotomy, we studied the distribution of moto-
neuron size of all motoneurons including those that are
< 300 μm
2 determined by their cross-sectional area in
the horizontal plane in all cells that were situated in the
ventral horn, had a nucleolus, and were CHAT-positive.
On the contralateral side, size distribution was similar
between the three genotypes (Figure 6, hatched bars;
BEG -/T CaMK -/T (442.55 ± 11.08 μm
2); BEG -/T
CaMK -/- (431.84 ± 12.52 μm
2); wt (434.20 ± 9.74 μm
2);
p = 0.78 by ANOVA).
On the ipsilateral (axotomized) side, there was a
downward shift in the mean size of the motoneurons in
the littermates that did not overexpress G-CSF (wt and
BEG -/T CaMK-/-). On the contrary, double transgenic
animals (BEG -/T CaMK -/T) displayed a relatively pre-
served motoneuron size, suggesting a healthier state of
those cells (Figure 6, solid bars; BEG -/T CaMK -/T
(464 ± 17 μm
2); BEG -/T CaMK -/- (391 ± 12 μm
2); wt
(353 ± 13 μm
2); p < 0.001; ANOVA followed by Fisher’s
LSD). This result was also obtained if we only consider
the a motoneurons that were counted for determining
cell survival (> 300 μm
2): 555.85 ± 17.43 μm
2 (BEG -/T
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Figure 5 Overexpression of G-CSF improves motoneuron
survival following sciatic nerve axotomy in neonatal pups. (A)
Quantification of the absolute number of a; motoneurons per
section of the lumbar spinal cord on the contralateral (unlesioned)
side. Numbers are not significantly different between the three
genotypes studied. (B) On the axotomized side numbers of
detectable motoneurons are dramatically decreased in the
littermate animals lacking the CaMK-tta driver transgene (wt, BEG -/-
CaMK-/-; and BEG -/T CaMK-/-), whereas overexpression of G-CSF in
the CNS results in significantly higher numbers of surviving
motoneurons (***p < 0.0001 by ANOVA and Fisher’s LSD post-hoc
analysis). (C) Percentage of surviving motoneurons on the ipsilateral
(axotomized) relative to the corresponding contralateral (control)
side. While only 50 - 60% of the motoneurons survive in the
genotypes lacking the CaMK-tta driver transgene, close to 90% of
the motoneurons survive in the presence of the driver (i.e. in
animals overexpressing G-CSF) (***p < 0.0001 by ANOVA and
Fisher’s LSD post-hoc analysis). (Number of animals: wt, n = 13; BEG
-/T CaMK -/-, n = 6; BEG -/T CaMK -/T, n = 7; 6 sections were
studied per animal).
Figure 6 Size distribution of surviving neurons in the spinal
cord of neonatal mice following sciatic nerve axotomy. On the
contralateral side (hatched bars) the size distribution between the
three genotypes is similar. On the ipsilateral side (filled bars) there is
a downward shift in the mean size of the surviving motoneurons in
the littermates without overexpression of G-CSF (BEG -/- CaMK -/-;
BEG -/T CaMK -/-). (p < 0.0001 for BEG -/T CaMK -/T vs. BEG -/-
CaMK -/-; **p = 0.0008 for BEG -/T CaMK -/T vs. BEG -/T CaMK -/-;
ANOVA followed by Fisher’s LSD; Number of motoneurons
measured: wt, n = 301; BEG -/T CaMK -/-, n = 197; BEG -/T CaMK -/T,
n = 227).
Henriques et al. BMC Neuroscience 2010, 11:25
http://www.biomedcentral.com/1471-2202/11/25
Page 5 of 9CaMK -/T); 484.32 ± 19.73 μm
2 ( B E G- / TC a M K- / - ) ;
477.68 ± 17.93 μm
2 ( w t ) ;p=0 . 0 0 2 9b yA N O V A .A d d i -
tional file 1 shows a histogram distribution of moto-
neurons contra- and ipsilateral to the axotomy. A
detailed summary of all data measured is given in addi-
tional file 2.
Discussion
Here we show that the receptor for G-CSF is expressed
by neonatal motoneurons and that G-CSF protects lum-
bar motoneurons in a model of neonatal sciatic nerve
axotomy. We have chosen this model because of the
clarity of the involved pathophysiology to obtain more
insight into the nature of G-CSF’s effect on motoneur-
ons. Sendtner et al. first described rescue of motoneuron
death caused by neonatal axotomy by the growth factor
CNTF [12]. This was followed by demonstration of a
number of other neurotrophic factors protective in this
paradigm. A series of papers then defined this axotomy-
induced motoneuron death as apoptosis, with involve-
ment of bcl proteins, AKT, IAPs, and caspases [14-16].
Overexpression of G-CSF protects lumbar motoneurons
to an extent that is comparable to many of the classic
neurotrophic factors. The experiments done here are
therefore a further step in redefining G-CSF as a neuro-
trophic factor.
On top of a relative increase of motoneuron numbers
following overexpression of G-CSF, we also noted an
increase of about 100 μm
2 in the mean cross-sectional
area of surviving motoneurons. This suggests a function-
ally more active, or healthier state of those motoneur-
ons. This has also been noted in adult SOD1(G93A)
mice by us previously [7]. This finding might point to
an additional trophic effect of G-CSF in addition to
counteracting apoptosis. Alternatively, this could signify
a proportionally greater anti-apoptotic effect size of G-
CSF on larger motoneurons which potentially express
more receptors on the cell surface.
We have studied motoneuron survival 4 days after
axotomy with the aim to demonstrate that G-CSF can
counteract apoptosis in motoneurons in vivo in a simple
paradigm as a mean to better dissect mechanisms of
action in the more complex ALS mouse models. We do
not know how transient this effect may be, and whether
increased survival would still be detectable at 1 month
after axotomy. All studies with growth factors in axot-
omy models that have examined varied time points after
axotomy found that the number of surviving neurons
declined with time to varying degrees in spite of
ongoing treatment [17,18]. The “slope” of this decline
might give an indication of the relative potency of
growth factors in this paradigm (e.g [18]). However,
there was always a lasting effect observed if growth fac-
tors showed protection after shorter observation time
points. The purpose of our study was however not to
compare relative efficacies of growth factors in this
paradigm. We prefer to study questions of relative effi-
cacy and effect stability in disease models closest and of
relevance to the human indication targeted, which is
ALS and SOD1-mutant mice in our case.
The observation that the G-CSF receptor was induced
by axotomy parallels findings from other neurological
disease models, such as stroke, spinal cord injury, or
ALS [6,7], and underlines the notion that the G-CSF
system is part of an endogenous protective system for
neurons. This is certainly an argument for the use of G-
CSF as a pharmacological agent that adresses an endo-
genously pre-specified mechanism. Indeed, G-CSF is
currently under clinical investigation in ischemic stroke
[19,20], and ALS [21-23].
We have undertaken this experiment to better dissect
mechanisms responsible for the previously demonstrated
beneficial function of G-CSF in the SOD1(G93A) mouse
model for ALS. We have chosen the axotomy model to
clearly answer the question whether G-CSF exerts a
direct influence on motoneuron apoptosis in vivo. We
have demonstrated potent anti-apoptotic properties of
this “redefined” neurotrophic factor in vitro either in
cortical neurons [6], or in motoneurons [7], and we
favoured the anti-apoptotic hypothesis due to the strong
effect on motoneuron survival in vivo. However, ALS is
a multifaceted disease, with many factors involved in the
pathophysiology [24-26], and the SOD1(G93A) models
reproduce this complexity with discussed involvement
of the neuromuscular junction, the immune system, glial
cells and others. Moreover, G-CSF is a pleiotropic factor
that for example also impacts on immunocompetence
and inflammatory reactions. The data presented here
clearly demonstrate a potent effect of G-CSF on moto-
neuron apoptosis in vivo, and support our assumption
that anti-apoptosis plays a central role in the observed
effects in the SOD1 transgenic ALS model.
Since G-CSF has such a potent protective role in
apoptosis mediated by cell-inherent mechanisms as a
response to nerve damage the interesting question arises
whether the G-CSF system might also play a role in
developmental death of motoneurons. This has indeed
been shown for a number of neurotrophic factors that
protect in the axotomy paradigm [27]. We do not
believe that this is a confounding factor in our case
since the expression of the CaMKII driven tTA is
switched on during P2 and P5 [28-30], while the sensi-
tive period for physiological motoneuron death is
between E14 and P3 [27].
Although we do not see significant effects on the
number of contralateral motoneurons in the different
transgenic crosses, there is an interesting trend (p = 0.1)
towards more motoneurons contralaterally in the G-CSF
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for the CaMKII tta driver. One might speculate that a
reason for this trend observation could be contralateral
effects of axotomy that are counteracted by G-CSF. This
slight nominal difference on the contralateral side does
however not change our result, since the protective
effect of G-CSF is also highly significant when regarding
ipsi-/contralateral ratios instead of ipsilateral cell
numbers.
The mechanisms responsible for counteraction of
apoptosis elicited by G-CSF in neurons have been pre-
viously delineated by us: Activation of AKT in neurons
and induction of stat3 and bcl-proteins [6]. The AKT
and stat3 pathways play a crucial role for the survival of
the axotomized motoneurons [31,32]. It is therefore
highly likely that G-CSF mediates its protective effect
via these pathways in the axotomy paradigm as well.
Conclusions
Here we have shown that G-CSF counteracts moto-
neuron death in a model of neonatal axotomy-induced
apoptosis. This is most likely mediated by direct actions
of the protein on motoneurons in vivo, and suggests
that the protection offered by G-CSF in ALS mouse
models is due to its direct neuroprotective activity.
Moreover, our data strengthen the overall evidence that
G-CSF is a candidate drug for the treatment of ALS.
Methods
Generation of G-CSF-overexpressing mice
Generation of the BEG transgenic lines is also described
in [7]. We cloned the cDNA for murine G-CSF in a bi-
directional Tet-transactivator (tta) responsive vector
(pBI, Clontech). EYFP was inserted on the other side of
the promoter for easy visualization of expression. To
generate the pBI-EYFP-G-CSF ("pBEG”) plasmid, G-CSF
was amplified from a mouse brain cDNA library and
inserted into the pBI Tet vector (Clontech) using the
restriction sites NheI and EcoRV. EYFP was inserted
into the multiple cloning site of the vector. Transgenic
mice ("BEG”) were generated, and selected for copy
number integration. Copy numbers were estimated by
quantitative PCR on genomic DNA by comparing
pBEG/cyclophilin ratios of wild type and founder mice.
For generating CNS- target G-CSF overexpressing mice,
m i c eo fl i n eB E G 6w e r ec r o s s e dw i t hm i c ee x p r e s s i n g
the Tet-transactivator under control of the CaMKII-pro-
moter (CaMKII-tta) [33], and successful activation of
the construct was verified by EYFP imaging.
Sciatic nerve injury
Neonatal mice were anesthetized and immobilized by
hypothermia after placement on ice, and unilateral scia-
tic nerve section was performed on postnatal day 5 (P5).
The skin of the right leg was incised parallel to the
femur. To expose the sciatic nerve a longitudinal cut
was made through the biceps femoris muscle with a
sharpened forceps. The right sciatic nerve was trans-
ected at midthighlevel, a small piece (about 1-2 mm in
length) of the nerve was removed to prevent reinnerva-
tion and the overlying skin of the thigh was sutured.
Pups were warmed and returned to the mother. All ani-
mal manipulation followed current regulations of and
were approved by the Regierungspräsidium Karlsruhe,
Germany.
Immunohistochemistry
After deep anesthesia spinal cords were removed
rapidly, immersed in 4% PFA, and embedded in paraffin.
For immunofluorescence, microtome sections of paraf-
fin-embedded tissues (10 μm) were deparaffinated and
microwaved (citrate buffer at 600 W for 15 min). For
double-fluorescence staining, sections were incubated
simultaneously with the G-CSF receptor antiserum (SC-
694; Santa Cruz Biotechnology, Santa Cruz, CA, USA;
1:100) and the CHAT antibody (AB144P; Chemicon
Europe Ltd., UK; 1:100) at 4°C overnight. After enhan-
cing the G-CSF receptor staining by adding a biotiny-
lated anti-rabbit secondary antibody (Dianova,
Hamburg, Germany; 1:200), sections were incubated
with a Streptavidin-coupled fluorophore (Invitrogen,
Karlsruhe, Germany; 1:200) or the appropriate fluores-
cence-coupled secondary antibody (Dianova, Hamburg,
Germany; 1:200). The nuclei were counterstained with
Hoechst 33342 (Molecular Probes, 1:10000). Controls
included omission of primary antibodies, fluorescence
swapping and single-fluorescence stainings. Pictures
were captured by video camera (Olympus DP71)
coupled to a fluorescent microscope (Olympus IX80).
To quantify staining intensity for the G-CSF receptor,
pictures were analyzed with an image processing pro-
gram (ImageJ). Intensity of grey levels were calculated
for each motoneuron and normalized to its area.
For light-microscopic CHAT-staining coronal paraffin
sections from the lumbar spinal cord (P9) were stained
with the CHAT antibody using the avidin-biotin com-
plex technique with DAB as chromogen (DakoCytoma-
tion), and counterstained with hemalaun.
Counting of motoneurons
Counting of motoneurons was performed at postnatal
day 9 (P9), i.e. 4 days following axotomy at P5. Spinal
cord paraffin sections of a thickness of 10 μm, spaced
by 100 μm over a length of 0.5 mm, were counted at
the spinal level L4-L5. Motor axons that constitute the
sciatic nerve in C57/bl6 mice originate from L3 to L5
[34]. All neurons in the ventral horn were counted as a
motoneurons if they had a clearly identifiable nucleolus,
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2 in size and were CHAT-positive. Count-
ing was performed with pictures acquired with the LMD
6000 microscope (Leica) and its system program.
Quantitative reverse transcription polymerase chain
reaction
RNA was isolated from spinal cords using RNeasy Mini
kit (Qiagen). Complementary DNA was synthesized
from 1 mg total RNA using oligo-dT primers and super-
script III reverse transcriptase (Invitrogen), according to
standard protocols. Quantitative reverse transcription-
polymerase chain reaction (RT-PCR) was performed
using the Lightcycler system (Roche) with SYBR-Green
staining of double-stranded DNA. Cycling conditions
were as follows: 10 min at 95°C; 5 s at 95°C, 10 s at the
annealing temperature of 64°C, 30 s at 72°C for 50
cycles and 10 min at 95°C. The following primers was
used: ‘G-CSFR-2582s’:TGT GCC CCA ACC TCC AAA
CCA;’G-CSFR-2817as’:GCT AGG GGC CAG AGA
CAG AGA CAC. Product specificity was ensured by
melting curve analysis and electrophoresis on agarose
gel. Relative regulation levels were derived after normali-
zation to cyclophilin: ‘cyc5’:ACC CCA CCG TGT TCT
TCG AC;’acyc300’:CAT TTG CCA TGG ACA AGA
TG.
Statistics
Experiments were performed in a completely rando-
mized and blinded manner. The experimenter was
blinded to the genotype of the animals at the time of
the experiment, and at the time of histological evalua-
tion. For comparisons of 2 groups the ttest was
employed. For 3 group comparisons, ANOVA was used,
followed by post-hoc Fisher’s test for contrasts. A p
value < 0.05 was considered statistically significant. Sta-
tistical analyses were done using JMP 7.0.1 (SAS
Institute).
Additional file 1: Description: Shown is the histogram distribution
of CHAT-positive cells in L4/5 for the 3 different genotypes
examined, and for the ipsi- and contralateral side.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-
25-S1.pdf]
Additional file 2: Description: Table of the motoneuron
quantification data. Given are the absolute numbers and percentages
of all CHAT positive cells; the mean size of all CHAT positive cells and
the number of a motoneurons per section for the 3 genotypes
examined (each for the ipsilateral and contralateral side).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2202-11-
25-S2.pdf]
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